(VIANEWS) – Oaktree Specialty Lending Corporation (OCSL), Compania Cervecerias Unidas, S.A. (CCU), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Oaktree Specialty Lending Corporation (OCSL)
31% sales growth and 6.1% return on equity
Oaktree Specialty Lending Corporation is a business development company. The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering. The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies. The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.
Earnings Per Share
As for profitability, Oaktree Specialty Lending Corporation has a trailing twelve months EPS of $1.23.
PE Ratio
Oaktree Specialty Lending Corporation has a trailing twelve months price to earnings ratio of 16.39. Meaning, the purchaser of the share is investing $16.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.1%.
2. Compania Cervecerias Unidas, S.A. (CCU)
26.1% sales growth and 8.98% return on equity
CompañÃa CervecerÃas Unidas S.A. operates as a beverage company principally in Chile, Argentina, Uruguay, Paraguay, Colombia, and Bolivia. The company operates through three segments: Chile, International Business, and Wine. It produces and sells alcoholic and non-alcoholic beer under proprietary and licensed brands, as well as distributes Pernod Ricard products in non-supermarket retail stores. The company also produces and sells non-alcoholic beverages, including carbonated soft drinks, nectars and juices, sports and energy drinks, and ice tea, as well as mineral, purified, and flavored bottled water, as well as ready-to-mix products with instant powder drinks. In addition, it is involved in the production and distribution of pisco, cocktails, rum, flavored alcoholic beverages, wine, cider, and spirits. The company serves small and medium-sized retail outlets; retail establishments, such as restaurants, hotels, and bars; wholesalers; and supermarket chains. It also exports its products to Europe, Latin America, the United States, Canada, Asia, Oceania, and internationally. The company was founded in 1850 and is based in Santiago, Chile. CompañÃa CervecerÃas Unidas S.A. is a subsidiary of Inversiones y Rentas S.A.
Earnings Per Share
As for profitability, Compania Cervecerias Unidas, S.A. has a trailing twelve months EPS of $0.74.
PE Ratio
Compania Cervecerias Unidas, S.A. has a trailing twelve months price to earnings ratio of 19.54. Meaning, the purchaser of the share is investing $19.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.98%.
Sales Growth
Compania Cervecerias Unidas, S.A.’s sales growth is 11.3% for the current quarter and 26.1% for the next.
Moving Average
Compania Cervecerias Unidas, S.A.’s worth is way under its 50-day moving average of $16.09 and below its 200-day moving average of $15.07.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 180% and 10.7%, respectively.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 19, 2023, the estimated forward annual dividend rate is 0.31 and the estimated forward annual dividend yield is 2.14%.
3. Vertex Pharmaceuticals (VRTX)
9.3% sales growth and 24.56% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.93.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.59. Meaning, the purchaser of the share is investing $26.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.56%.
Yearly Top and Bottom Value
Vertex Pharmaceuticals’s stock is valued at $343.87 at 01:22 EST, below its 52-week high of $367.00 and way above its 52-week low of $276.57.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Vertex Pharmaceuticals’s EBITDA is 8.21.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 9.51B for the twelve trailing months.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 12.1% for the current quarter and 9.3% for the next.
